



Formulation Development for Treatment of Tropical Diseases

Guest Editors:

Prof. Dr. Eder Lilia Romero

Department of Science and
Technology, Universidad
Nacional de Quilmes, Bernal
B1876, Argentina

Dr. Katrien Van Bocxlaer

Department of Biology, York
Biomedical Research Institute,
University of York, York YO10 5DD,
UK

Prof. Dr. Simon Croft

Department of Infection Biology,
London School of Hygiene and
Tropical Medicine, London WC1E
7HT, UK

Deadline for manuscript
submissions:

closed (1 June 2022)

Message from the Guest Editors

Dear Colleagues,

Many tropical diseases, a term that includes both diseases of poverty, like malaria, and the neglected tropical diseases, like leishmaniasis, Chagas disease, and mycetoma, are in urgent need of new treatments.

Formulation development, aimed at optimizing drug exposure at the biophase, has been a central part of the search for new treatments with varying levels of success. Nanotechnologies masking suboptimal API properties have been the key to treatment advances for visceral leishmaniasis. Another form of this disease, cutaneous leishmaniasis, has focused research on topical formulations. The multi-drug treatments for malaria and tuberculosis, with the demands for patient compliance and adherence, have ensured that co-formulations of fixed-dose combinations are to the fore.

This Special Issue presents articles describing the performance of novel antimicrobial, antiprotozoal, and anthelmintic formulations and nanomedicines administered by both systemic and local (topical, mucosal, or inhalation) routes, to optimize delivery and efficacy while ensuring minimal side effects.

Prof. Dr. Eder Lilia Romero

Dr. Katrien Van Bocxlaer

Prof. Dr. Simon Croft

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma